Cardiology Thesis Topics

Cardiology thesis topics represent a clinically vital and scientifically rich area within health thesis topics, drawing graduate students at American universities into a discipline that addresses the prevention, diagnosis, and treatment of diseases of the heart and cardiovascular system — the leading cause of death and disability in the United States. Cardiology encompasses coronary artery disease, heart failure, cardiac arrhythmias, valvular heart disease, congenital heart disease, pulmonary hypertension, and the growing fields of preventive cardiology, cardiac imaging, interventional cardiology, and electrophysiology. As cardiovascular disease continues to extract an enormous human and economic toll from American society — with persistent and widening racial and socioeconomic disparities in cardiovascular outcomes — the research questions animating cardiology thesis topics have never been more clinically urgent or scientifically productive.

Cardiology Thesis Topics and Research Areas

The discipline of cardiology research spans basic cardiovascular science, translational investigation, clinical trial methodology, health services research, and population-level cardiovascular epidemiology — offering graduate students research environments that range from molecular biology laboratories studying cardiac remodeling mechanisms to large administrative datasets characterizing cardiovascular care quality across American health systems. From investigating the genetic architecture of atrial fibrillation and developing novel heart failure pharmacotherapy to evaluating the cardiovascular health disparities facing Black Americans and designing preventive cardiology interventions for underserved communities, cardiology thesis topics engage with questions of profound biological complexity and immediate human consequence. The 200 cardiology thesis topics organized below into 10 thematic categories are designed to be research-ready at American cardiology fellowship research programs, cardiovascular epidemiology doctoral programs, and academic medical centers with comprehensive cardiovascular research infrastructure.

1. Coronary Artery Disease and Acute Coronary Syndromes

Coronary artery disease remains the single leading cause of death in the United States, and the acute coronary syndromes — unstable angina, non-ST-elevation myocardial infarction, and ST-elevation myocardial infarction — represent the most time-critical cardiovascular emergencies managed across American hospital systems. This category of cardiology thesis topics addresses the pathophysiology of coronary atherosclerosis, the epidemiology and risk factor burden of coronary artery disease in American populations, the comparative effectiveness of revascularization strategies, and the secondary prevention interventions that reduce recurrent cardiovascular events after acute coronary syndromes. Graduate students contribute to understanding both the biological mechanisms driving coronary disease and the health system factors that determine whether American patients receive optimal evidence-based care.

1. Investigating the relationship between coronary artery calcium score progression and major adverse cardiovascular event risk in American adults with intermediate cardiovascular risk using prospective cohort methodology
2. Analyzing the sex differences in acute myocardial infarction presentation, treatment delays, and in-hospital outcomes across American hospitals using National Cardiovascular Data Registry data
3. Developing a machine learning model for predicting thirty-day readmission following acute myocardial infarction in American Medicare beneficiaries using electronic health record and claims data
4. Characterizing the racial and ethnic disparities in door-to-balloon time performance and clinical outcomes for ST-elevation myocardial infarction across American percutaneous coronary intervention-capable hospitals
5. Investigating the long-term cardiovascular outcomes of complete versus culprit-only revascularization strategies in American patients with ST-elevation myocardial infarction and multivessel disease
6. Analyzing the high-sensitivity troponin-based accelerated diagnostic protocol effectiveness for safe early discharge of American emergency department patients with suspected acute coronary syndromes
7. Developing a cardiovascular risk prediction model incorporating traditional risk factors and novel biomarkers including lipoprotein(a) and high-sensitivity C-reactive protein for American primary prevention populations
8. Characterizing the geographic variation in cardiac catheterization and percutaneous coronary intervention utilization rates across American hospital referral regions and its relationship to outcomes
9. Investigating the effectiveness of a pharmacist-led secondary prevention program for improving guideline-directed medical therapy adherence in American adults following acute myocardial infarction
10. Analyzing the prognostic significance of coronary microvascular dysfunction detected by cardiac magnetic resonance imaging in American women with ischemia and non-obstructive coronary arteries
11. Developing a patient decision aid for coronary revascularization choices in American adults with stable ischemic heart disease and evaluating its impact on decisional quality and treatment concordance
12. Characterizing the socioeconomic determinants of statin therapy adherence and low-density lipoprotein cholesterol goal attainment in American adults with established atherosclerotic cardiovascular disease
13. Investigating the cardiovascular outcomes associated with colchicine therapy for residual inflammatory risk reduction in American adults with recent acute myocardial infarction using a randomized trial design
14. Analyzing the relationship between air pollution exposure and acute myocardial infarction incidence in American urban populations using time-series and case-crossover epidemiological methodology
15. Developing a structured cardiac rehabilitation referral and enrollment program for American hospitals and evaluating its effectiveness in increasing participation rates among eligible post-myocardial infarction patients
16. Characterizing the plaque morphology characteristics detected by coronary computed tomography angiography associated with future acute coronary syndrome risk in American intermediate-risk populations
17. Investigating the comparative effectiveness of drug-eluting stent versus coronary artery bypass grafting for left main coronary artery disease in American patients using propensity-matched registry data
18. Analyzing the relationship between psychological stress, depression, and recurrent cardiovascular events in American adults following first acute myocardial infarction using validated psychological assessment methodology
19. Developing a telehealth-delivered cardiac rehabilitation program for American adults in rural communities without access to center-based programs and evaluating its equivalence to in-person rehabilitation
20. Characterizing the long-term cardiovascular outcomes and quality of life following spontaneous coronary artery dissection in American women using multicenter registry and patient-reported outcome methodology

2. Heart Failure

Heart failure affects more than six million Americans and is the leading cause of hospitalization in Medicare beneficiaries — creating an enormous clinical burden and a rich research landscape addressing the molecular mechanisms of cardiac remodeling, novel pharmacotherapy, device-based therapy, and the health system innovations needed to reduce the devastating cycle of hospitalization and readmission that characterizes advanced heart failure in America. This category of cardiology thesis topics encompasses heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, advanced heart failure therapies, and the implementation of guideline-directed medical therapy across American heart failure populations.

21. Investigating the comparative effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy on cardiovascular mortality and heart failure hospitalization in American heart failure with reduced ejection fraction populations using real-world data
22. Analyzing the clinical phenotypes and treatment response heterogeneity in American patients with heart failure with preserved ejection fraction using unsupervised machine learning cluster analysis of multi-biomarker data
23. Developing a remote patient monitoring program for American heart failure patients using daily weight, blood pressure, and symptom assessment with nurse-led telehealth oversight and evaluating readmission reduction
24. Characterizing the racial disparities in guideline-directed medical therapy prescription rates and dosing adequacy for American Black patients with heart failure with reduced ejection fraction across cardiology practices
25. Investigating the prognostic significance of cardiac rehabilitation participation on exercise capacity and mortality in American adults with heart failure with reduced ejection fraction using propensity-matched cohort methodology
26. Analyzing the SGLT2 inhibitor therapy initiation patterns and clinical outcome improvements in American heart failure with reduced ejection fraction patients following landmark trial publication
27. Developing a palliative care integration model for American patients with advanced heart failure and evaluating its impact on symptom burden, goal-concordant care, and end-of-life quality
28. Characterizing the right ventricular dysfunction prevalence and its prognostic significance for adverse outcomes in American patients with heart failure with preserved ejection fraction
29. Investigating the effectiveness of an interdisciplinary heart failure disease management program on thirty-day readmission rates and quality of life in American safety-net hospital populations
30. Analyzing the iron deficiency prevalence and intravenous ferric carboxymaltose therapy outcomes in American patients with heart failure with reduced ejection fraction and iron deficiency without anemia
31. Developing a machine learning model for predicting acute decompensated heart failure hospitalization from continuous remote monitoring data in American outpatient heart failure populations
32. Characterizing the cardiomyopathy genetic architecture in American patients with new-onset heart failure using clinical whole-exome sequencing and evaluating the therapeutic and familial screening implications
33. Investigating the long-term outcomes and mechanical circulatory support bridge-to-decision strategy effectiveness for American patients with acute cardiogenic shock complicating acute myocardial infarction
34. Analyzing the transcatheter mitral valve repair outcomes for functional mitral regurgitation in American patients with heart failure with reduced ejection fraction using Society of Thoracic Surgeons registry data
35. Developing a frailty assessment and optimization protocol for American patients with advanced heart failure being evaluated for left ventricular assist device implantation or cardiac transplantation
36. Characterizing the natriuretic peptide-guided heart failure therapy titration effectiveness for improving guideline-directed medical therapy dosing and reducing heart failure events in American outpatient cardiology settings
37. Investigating the wearable cardioverter-defibrillator utilization patterns and appropriate shock delivery rates in American patients with newly diagnosed heart failure with reduced ejection fraction
38. Analyzing the sodium restriction effectiveness and patient adherence to dietary sodium recommendations in American heart failure patients across different education and socioeconomic backgrounds
39. Developing a structured transition of care program for American heart failure patients discharged from hospital and evaluating its effectiveness in reducing thirty-day readmission through early follow-up and medication optimization
40. Characterizing the sleep-disordered breathing prevalence and adaptive servo-ventilation therapy outcomes in American patients with heart failure with reduced ejection fraction and central sleep apnea

3. Cardiac Arrhythmias and Electrophysiology

Cardiac arrhythmias — encompassing atrial fibrillation, ventricular tachycardia, bradyarrhythmias, and inherited channelopathies — affect millions of Americans and range from nuisances requiring lifestyle modification to life-threatening emergencies requiring immediate intervention. This category of cardiology thesis topics addresses arrhythmia mechanisms, catheter ablation outcomes, antiarrhythmic pharmacotherapy, implantable device management, and the growing field of cardiac electrophysiology in special populations including athletes, elderly adults, and those with structural heart disease. Graduate students contribute to understanding both the biological basis of arrhythmias and the optimal strategies for their management across American electrophysiology programs.

41. Investigating the catheter ablation versus antiarrhythmic drug therapy comparative effectiveness for reducing cardiovascular hospitalization and mortality in American patients with atrial fibrillation and heart failure
42. Analyzing the wearable device-detected subclinical atrial fibrillation clinical significance and anticoagulation decision-making implications in American adults without known atrial fibrillation
43. Developing a machine learning algorithm for predicting new-onset atrial fibrillation from twelve-lead electrocardiogram features in American adults without prior arrhythmia diagnosis
44. Characterizing the racial and socioeconomic disparities in catheter ablation access and outcomes for atrial fibrillation across American electrophysiology centers using national procedure registry data
45. Investigating the pulmonary vein isolation durability and atrial fibrillation recurrence predictors in American patients undergoing repeat catheter ablation procedures using high-density electroanatomical mapping
46. Analyzing the direct oral anticoagulant versus warfarin comparative effectiveness and safety for stroke prevention in American atrial fibrillation patients with chronic kidney disease
47. Developing a risk stratification tool for sudden cardiac death in American patients with hypertrophic cardiomyopathy using clinical, genetic, and imaging variables from a multicenter registry
48. Characterizing the subcutaneous implantable cardioverter-defibrillator versus transvenous implantable cardioverter-defibrillator outcomes in American patients without bradycardia or cardiac resynchronization therapy indications
49. Investigating the cardiac resynchronization therapy response predictors and long-term survival outcomes in American patients with heart failure with reduced ejection fraction and left bundle branch block
50. Analyzing the inherited arrhythmia syndrome genetic testing yield and cascade family screening outcomes in American patients with long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia
51. Developing a remote monitoring program for American patients with implantable cardiac devices and evaluating its effectiveness in reducing inappropriate shocks and improving arrhythmia detection accuracy
52. Characterizing the ventricular tachycardia catheter ablation outcomes and recurrence predictors in American patients with ischemic and non-ischemic cardiomyopathy using multicenter ablation registry data
53. Investigating the left atrial appendage occlusion device outcomes and anticoagulation cessation safety in American atrial fibrillation patients with high bleeding risk using prospective registry methodology
54. Analyzing the atrial fibrillation burden quantification from implantable loop recorder data and its relationship to stroke risk and anticoagulation benefit threshold in American patients
55. Developing a digital health platform for rhythm monitoring and symptom tracking in American patients with paroxysmal atrial fibrillation and evaluating its impact on arrhythmia detection and treatment decisions
56. Characterizing the sports cardiology evaluation outcomes and return-to-play decision patterns for American competitive athletes with newly detected cardiac arrhythmias or structural abnormalities
57. Investigating the leadless pacemaker implantation outcomes and complication rates compared to traditional transvenous pacing in American elderly patients with bradyarrhythmia indications
58. Analyzing the relationship between obstructive sleep apnea treatment and atrial fibrillation recurrence following catheter ablation in American patients with coexisting sleep-disordered breathing
59. Developing an electrophysiology laboratory quality metrics program for American catheter ablation centers and evaluating its relationship to procedural outcomes and complication rates
60. Characterizing the genetic architecture and clinical phenotype spectrum of familial atrial fibrillation in American multigenerational kindreds using whole-genome sequencing and deep clinical phenotyping

4. Preventive Cardiology and Cardiovascular Risk Reduction

Preventive cardiology addresses the upstream determinants of cardiovascular disease — encompassing lipid management, hypertension control, diabetes prevention, lifestyle modification, and the population-level strategies needed to reduce the enormous cardiovascular disease burden afflicting American adults. This category of cardiology thesis topics draws on epidemiology, behavioral science, pharmacology, and health policy to examine how cardiovascular risk can be identified earlier, modified more effectively, and reduced more equitably across the diverse American population. Graduate students contribute to the evidence base for both individual-level preventive interventions and population-level cardiovascular health promotion strategies.

61. Investigating the cardiovascular event reduction benefit of inclisiran RNA interference therapy for low-density lipoprotein cholesterol lowering in American patients with atherosclerotic cardiovascular disease and statin intolerance
62. Analyzing the lipoprotein(a) concentration distribution and its independent cardiovascular risk contribution in American adults from diverse racial and ethnic backgrounds using population biobank data
63. Developing a cardiovascular primary prevention shared decision-making program for American adults with intermediate risk scores and evaluating its impact on statin initiation and cardiovascular risk factor control
64. Characterizing the hypertension control rates and antihypertensive therapy intensification patterns across American primary care practices by patient race, insurance type, and practice setting
65. Investigating the effectiveness of a pharmacist-led hypertension management program in American community pharmacy settings on blood pressure control and cardiovascular risk factor modification
66. Analyzing the cardiovascular risk factor burden and lifetime cardiovascular risk trajectories in American young adults aged eighteen to thirty-nine using NHANES and longitudinal cohort data
67. Developing a community-based cardiovascular health promotion program for American Black adults using barbershop and beauty salon settings and evaluating its effectiveness on blood pressure and cardiovascular risk knowledge
68. Characterizing the dietary pattern associations with subclinical atherosclerosis progression in American adults using coronary artery calcium score tracking and dietary assessment methodology
69. Investigating the cardiovascular protective effects of GLP-1 receptor agonist therapy beyond glycemic control in American adults with type 2 diabetes and established or high cardiovascular risk
70. Analyzing the blood pressure variability patterns and their independent cardiovascular outcome prediction beyond mean blood pressure in American adults with hypertension using ambulatory monitoring data
71. Developing a digital health-supported cardiovascular risk reduction program for American adults with metabolic syndrome using personalized coaching, remote monitoring, and telehealth follow-up
72. Characterizing the statin therapy underutilization patterns and prescribing barriers for American adults with established atherosclerotic cardiovascular disease across primary care and cardiology practice settings
73. Investigating the cardiovascular health consequences of food insecurity in American adults and evaluating the cardiovascular risk modification potential of food prescription program interventions
74. Analyzing the relationship between psychosocial stressors — including job strain, discrimination, and neighborhood disadvantage — and subclinical cardiovascular disease in American middle-aged adults
75. Developing a cardiovascular prevention program for American women with a history of adverse pregnancy outcomes including preeclampsia and gestational diabetes and evaluating its risk reduction effectiveness
76. Characterizing the precision medicine approach to statin therapy selection using pharmacogenomic predictors of statin-induced myopathy and cardiovascular response in American preventive cardiology populations
77. Investigating the cardiovascular health impact of neighborhood greenspace access and built environment walkability in American urban communities using geospatial and electronic health record linkage methodology
78. Analyzing the omega-3 fatty acid supplementation cardiovascular outcome effects across different formulations and doses in American adults with and without established cardiovascular disease
79. Developing a structured hypertension management program for American adults with resistant hypertension using aldosterone-to-renin ratio testing and mineralocorticoid receptor antagonist optimization
80. Characterizing the cardiovascular risk factor control quality and cardiovascular outcome disparities between American adults with private insurance versus Medicaid coverage using multi-state claims data

5. Cardiac Imaging

Cardiac imaging has become the cornerstone of cardiovascular diagnosis and risk stratification — with echocardiography, cardiac magnetic resonance imaging, coronary computed tomography angiography, nuclear cardiology, and invasive coronary imaging providing complementary windows into cardiac structure, function, and physiology. This category of cardiology thesis topics addresses imaging protocol development and optimization, novel imaging biomarkers, the comparative diagnostic value of different modalities, and the application of artificial intelligence to cardiac image interpretation. Graduate students at American cardiovascular imaging programs contribute to advancing the science and clinical application of cardiac imaging across diverse patient populations.

81. Investigating the coronary computed tomography angiography fractional flow reserve diagnostic accuracy for functional ischemia assessment compared to invasive fractional flow reserve in American stable chest pain populations
82. Analyzing the cardiac magnetic resonance imaging late gadolinium enhancement pattern significance and arrhythmic risk prediction in American patients with non-ischemic dilated cardiomyopathy
83. Developing a deep learning algorithm for automated echocardiographic image quality assessment and view classification from transthoracic echocardiograms in American cardiology laboratory settings
84. Characterizing the strain echocardiography subclinical left ventricular dysfunction detection capability in American cancer patients receiving cardiotoxic chemotherapy for breast cancer
85. Investigating the cardiac magnetic resonance imaging protocol optimization for tissue characterization in American patients with suspected cardiac sarcoidosis using T1 and T2 mapping sequences
86. Analyzing the coronary computed tomography angiography calcium scoring performance for cardiovascular risk reclassification beyond traditional risk factors in American intermediate-risk primary prevention populations
87. Developing a point-of-care ultrasound training program for American internal medicine residents and evaluating its impact on cardiac examination accuracy and clinical decision-making quality
88. Characterizing the right heart catheterization hemodynamic profile patterns and their therapeutic implications in American patients with pulmonary hypertension across different etiological subtypes
89. Investigating the cardiac positron emission tomography viability assessment clinical outcomes and revascularization decision impact in American patients with ischemic cardiomyopathy and reduced left ventricular function
90. Analyzing the transthoracic echocardiography diastolic function grading reliability and interobserver variability in American echocardiography laboratories using ASE guideline criteria
91. Developing an AI-assisted echocardiographic interpretation platform and evaluating its impact on report turnaround time and ejection fraction measurement accuracy in American cardiology practices
92. Characterizing the cardiac magnetic resonance imaging myocardial perfusion assessment accuracy compared to single-photon emission computed tomography for ischemia detection in American chest pain populations
93. Investigating the intravascular ultrasound-guided versus angiography-guided percutaneous coronary intervention outcomes in American patients with complex coronary lesion morphology
94. Analyzing the multimodality cardiac imaging approach effectiveness for guiding transcatheter structural heart disease interventions in American centers performing high volumes of complex procedures
95. Developing a standardized cardiac magnetic resonance imaging reporting template for cardiomyopathy characterization and evaluating its inter-reader reliability across American cardiovascular imaging centers
96. Characterizing the coronary computed tomography angiography pericoronary adipose tissue attenuation patterns and their relationship to coronary inflammation and adverse cardiac events in American cohorts
97. Investigating the handheld ultrasound device diagnostic accuracy for detecting major echocardiographic abnormalities compared to standard transthoracic echocardiography in American primary care settings
98. Analyzing the cardiac magnetic resonance imaging T1 mapping extracellular volume fraction patterns in American patients with different stages of heart failure with preserved ejection fraction
99. Developing a multimodality imaging-based risk stratification protocol for American patients with severe aortic stenosis being evaluated for transcatheter versus surgical aortic valve replacement
100. Characterizing the artificial intelligence model performance for automated detection of regional wall motion abnormalities from transthoracic echocardiographic images in American cardiology laboratory settings

6. Structural Heart Disease and Interventional Cardiology

Structural heart disease interventions have been transformed by transcatheter technologies — with transcatheter aortic valve replacement, transcatheter mitral valve repair, left atrial appendage occlusion, and patent foramen ovale closure now representing mainstream treatment options for American patients who were previously denied surgery due to high operative risk. This category of cardiology thesis topics addresses the clinical outcomes of structural heart disease interventions, patient selection optimization, procedural technique innovation, and the health services research questions surrounding the rapid adoption of transcatheter therapies across American cardiac catheterization laboratories.

101. Investigating the long-term durability and structural valve deterioration rates of transcatheter aortic valve replacement bioprostheses in American patients at low surgical risk using five-year follow-up echocardiographic data
102. Analyzing the transcatheter mitral valve repair clinical outcomes stratified by mitral regurgitation etiology — primary degenerative versus secondary functional — in American structural heart disease program registries
103. Developing a multidisciplinary heart team decision framework for selecting between transcatheter and surgical aortic valve replacement in American intermediate-risk patients with severe aortic stenosis
104. Characterizing the vascular access complication rates and management strategies for transfemoral transcatheter aortic valve replacement across American centers with different volume and experience levels
105. Investigating the patent foramen ovale closure versus antiplatelet therapy comparative effectiveness for secondary stroke prevention in American adults with cryptogenic stroke and patent foramen ovale
106. Analyzing the transcatheter tricuspid valve intervention clinical outcomes and patient selection criteria in American patients with severe tricuspid regurgitation and high surgical risk
107. Developing a cardiac rehabilitation program specifically adapted for American patients following transcatheter structural heart disease interventions and evaluating its functional recovery outcomes
108. Characterizing the hemodynamic outcomes and clinical benefit of transcatheter aortic valve replacement in American patients with low-gradient severe aortic stenosis and preserved left ventricular function
109. Investigating the intravascular lithotripsy effectiveness for enabling transcatheter heart valve delivery through severely calcified peripheral vascular access sites in American structural heart disease patients
110. Analyzing the mitral annuloplasty ring selection and repair technique outcomes for degenerative mitral regurgitation repair in American centers with high surgical volume using Society of Thoracic Surgeons data
111. Developing a patient-reported outcome measurement program for American transcatheter aortic valve replacement recipients and evaluating health status improvements and patient satisfaction at one year
112. Characterizing the conduction system disturbance patterns and permanent pacemaker implantation rates following transcatheter aortic valve replacement across different valve platform designs in American centers
113. Investigating the hypertrophic cardiomyopathy septal reduction therapy outcomes — surgical myectomy versus alcohol septal ablation — in American patients with obstructive hypertrophic cardiomyopathy
114. Analyzing the transcatheter pulmonary valve replacement outcomes in American adults with congenital heart disease and right ventricular outflow tract dysfunction using multicenter registry data
115. Developing a simulation-based training curriculum for American structural heart disease fellows learning transcatheter aortic valve replacement implantation technique using high-fidelity cardiac catheterization simulators
116. Characterizing the anticoagulation management strategy outcomes following transcatheter aortic valve replacement in American patients with and without concurrent atrial fibrillation
117. Investigating the clinical outcomes of percutaneous ventricular assist device support during high-risk percutaneous coronary intervention in American patients with severely reduced left ventricular function
118. Analyzing the atrial septal defect and patent foramen ovale closure device outcomes in American adults using the NCDR IMPACT registry and evaluating the relationship between operator volume and outcomes
119. Developing a quality metrics dashboard for American structural heart disease programs that tracks procedural outcomes, complication rates, and patient-reported outcomes across transcatheter interventions
120. Characterizing the repeat transcatheter aortic valve replacement valve-in-valve procedure feasibility and hemodynamic outcomes in American patients with degenerated surgical bioprosthetic valves

7. Cardiovascular Genetics and Inherited Heart Disease

Cardiovascular genetics has emerged as a distinct and rapidly growing subspecialty — encompassing inherited cardiomyopathies, familial hypercholesterolemia, inherited arrhythmia syndromes, and aortopathies — with genetic testing increasingly informing diagnosis, risk stratification, family screening, and therapeutic decision-making in American cardiology practice. This category of cardiology thesis topics addresses genetic testing methodology, variant classification, the clinical management of genotype-positive phenotype-negative family members, and the equitable implementation of cardiovascular genetics services across diverse American populations.

121. Investigating the clinical genetic testing yield and variant of uncertain significance reclassification rates in American patients with inherited cardiomyopathy using comprehensive gene panel testing with long-term follow-up
122. Analyzing the familial hypercholesterolemia cascade screening effectiveness and low-density lipoprotein cholesterol treatment outcomes in American families with index cases identified through lipid clinic screening
123. Developing a cardiovascular genetics clinic model for American academic medical centers and evaluating its impact on genetic testing completion, variant interpretation, and family cascade screening rates
124. Characterizing the transthyretin amyloid cardiomyopathy prevalence in American Black adults with heart failure with preserved ejection fraction using technetium pyrophosphate scintigraphy screening
125. Investigating the genotype-phenotype correlations and clinical outcome predictors in American patients with LMNA-related dilated cardiomyopathy using multicenter registry and genetic data linkage
126. Analyzing the arrhythmogenic cardiomyopathy genetic architecture and phenotypic expression patterns in American families with desmosomal gene variants using cardiac magnetic resonance imaging and Holter data
127. Developing a polygenic risk score for coronary artery disease and evaluating its clinical utility for risk reclassification and preventive therapy intensification in American intermediate-risk primary prevention populations
128. Characterizing the Marfan syndrome and related thoracic aortopathy natural history and aortic root replacement timing outcomes in American patients using multicenter aortic disease registry data
129. Investigating the hypertrophic cardiomyopathy genetic testing patterns, variant classification challenges, and cascade screening uptake in American families using cardiology genetics program registry data
130. Analyzing the equity of cardiovascular genetic testing access and cascade screening completion across racial and socioeconomic groups in American cardiology and genetics practice settings
131. Developing a patient education and shared decision-making tool for American adults receiving pathogenic cardiovascular gene variant results and evaluating its impact on psychological adjustment and preventive behavior
132. Characterizing the return of incidental cardiovascular genetic findings from biobank whole-genome sequencing in American participants and evaluating clinical management patterns and outcomes
133. Investigating the pharmacogenomic predictors of clopidogrel response and clinical outcomes in American patients undergoing percutaneous coronary intervention using CYP2C19 genotyping methodology
134. Analyzing the genetic testing uptake and barriers among American Black and Hispanic patients with inherited cardiomyopathy compared to white patients at academic cardiology genetics programs
135. Developing a variant of uncertain significance reclassification protocol for American cardiology genetics programs using functional evidence, population data, and computational prediction integration

8. Heart Failure with Preserved Ejection Fraction and Cardiometabolic Disease

Heart failure with preserved ejection fraction has emerged as the dominant heart failure phenotype in American adults — particularly among older women, those with obesity, hypertension, and diabetes — yet it remains inadequately understood and historically undertreated compared to heart failure with reduced ejection fraction. This category of cardiology thesis topics addresses the pathophysiology of heart failure with preserved ejection fraction, the cardiometabolic risk factor interactions that drive its development, the emerging pharmacotherapy evidence including SGLT2 inhibitors, and the lifestyle and behavioral interventions that can modify its trajectory in American populations.

136. Investigating the SGLT2 inhibitor therapy clinical outcome improvements in American patients with heart failure with preserved ejection fraction stratified by ejection fraction range and comorbidity burden
137. Analyzing the obesity-related cardiac remodeling mechanisms and their reversibility following significant weight loss achieved through GLP-1 receptor agonist therapy in American adults with heart failure with preserved ejection fraction
138. Developing a comprehensive cardiac rehabilitation program adapted for American patients with heart failure with preserved ejection fraction and evaluating its impact on exercise capacity and quality of life
139. Characterizing the diastolic stress testing protocol performance for unmasking exercise-induced elevated filling pressures in American adults with exertional dyspnea and resting preserved ejection fraction
140. Investigating the relationship between adipose tissue inflammation, epicardial fat volume, and diastolic dysfunction severity in American adults with obesity and heart failure with preserved ejection fraction
141. Analyzing the atrial fibrillation contribution to heart failure with preserved ejection fraction hospitalization and mortality in American Medicare beneficiaries using linked claims and echocardiography data
142. Developing a phenomapping approach for identifying distinct heart failure with preserved ejection fraction subtypes in American patients and evaluating subtype-specific treatment response patterns
143. Characterizing the exercise intolerance mechanisms in American patients with heart failure with preserved ejection fraction using cardiopulmonary exercise testing with invasive hemodynamic assessment
144. Investigating the aldosterone excess contribution to heart failure with preserved ejection fraction pathophysiology and spironolactone response heterogeneity in American outpatient cardiology populations
145. Analyzing the sleep-disordered breathing treatment impact on diastolic function and exercise capacity in American adults with obesity-related heart failure with preserved ejection fraction

9. Cardiovascular Health Disparities and Social Determinants

Cardiovascular disease mortality in the United States falls disproportionately on Black Americans, low-income communities, rural populations, and other socially marginalized groups — disparities that reflect the cumulative cardiovascular toll of structural racism, economic deprivation, environmental hazard exposure, and differential access to preventive and acute cardiovascular care. This category of cardiology thesis topics examines the mechanisms, magnitude, and potential solutions for cardiovascular health disparities in America — drawing on epidemiology, social science, health services research, and community-engaged research to understand and address the structural determinants of inequitable cardiovascular outcomes.

146. Investigating the relationship between cumulative lifetime racism exposure and subclinical cardiovascular disease — including coronary artery calcium and carotid intima-media thickness — in American Black adults
147. Analyzing the cardiovascular mortality rate trends by race, ethnicity, and socioeconomic status across American counties over the past three decades using vital statistics and census data linkage
148. Developing a community health worker-led cardiovascular risk reduction program for American Black adults in high-cardiovascular-burden urban communities and evaluating its blood pressure and cholesterol outcomes
149. Characterizing the social determinants of heart failure readmission risk in American safety-net hospital populations and evaluating the effectiveness of social needs screening and referral interventions
150. Investigating the relationship between neighborhood poverty, food environment quality, and incident cardiovascular disease in American adults using longitudinal cohort data with geocoded residential history
151. Analyzing the cardiovascular care quality disparities between American rural and urban hospitals for acute myocardial infarction management including reperfusion time performance and evidence-based medication use
152. Developing a structural competency curriculum for American cardiology fellows that addresses how social and economic determinants shape cardiovascular disease risk and care quality for their patients
153. Characterizing the cardiovascular health consequences of concentrated poverty and residential segregation in American metropolitan areas using multilevel epidemiological methodology
154. Investigating the impact of Medicaid expansion under the Affordable Care Act on cardiovascular disease diagnosis rates, treatment initiation, and outcomes in American low-income adult populations
155. Analyzing the implicit bias patterns in American cardiologist clinical decision-making for cardiac catheterization referral and treatment intensity across patient racial and gender groups

10. Advanced Heart Failure and Cardiac Transplantation

Advanced heart failure management — encompassing left ventricular assist device therapy, cardiac transplantation, palliative care for refractory heart failure, and the complex medical management of end-stage heart disease — represents a specialized and rapidly evolving area of cardiology with important questions about patient selection, device management, post-transplant outcomes, and the equitable allocation of scarce donor hearts across American transplant centers.

156. Investigating the left ventricular assist device destination therapy long-term survival and adverse event outcomes in American patients with advanced heart failure ineligible for cardiac transplantation
157. Analyzing the racial disparities in cardiac transplantation waitlist mortality, organ offer acceptance rates, and post-transplant survival in American heart transplant centers using UNOS registry data
158. Developing a palliative care needs assessment and integration protocol for American patients with advanced heart failure on left ventricular assist device support and evaluating its symptom management outcomes
159. Characterizing the driveline infection prevention strategies and their effectiveness across American left ventricular assist device implanting centers using the Interagency Registry for Mechanically Assisted Circulatory Support
160. Investigating the cardiac transplantation outcomes in American adults with congenital heart disease compared to cardiomyopathy recipients using multi-decade UNOS registry data analysis
161. Analyzing the primary graft dysfunction risk factors and management strategies in American cardiac transplantation centers and their relationship to early and late post-transplant mortality
162. Developing a frailty measurement and prehabilitation program for American patients awaiting cardiac transplantation and evaluating its impact on post-transplant functional recovery and outcomes
163. Characterizing the immunosuppression minimization strategy outcomes and rejection surveillance approaches in American long-term cardiac transplant survivors beyond ten years post-transplantation
164. Investigating the temporary mechanical circulatory support strategy outcomes — including Impella, intra-aortic balloon pump, and extracorporeal membrane oxygenation — for American cardiogenic shock patients
165. Analyzing the geographic access disparities to advanced heart failure therapies including left ventricular assist device implantation and cardiac transplantation across American hospital referral regions

11. Cardio-Oncology

Cardio-oncology has emerged as one of the most rapidly growing cardiology subspecialties — addressing the cardiovascular toxicity of cancer treatments including anthracyclines, trastuzumab, tyrosine kinase inhibitors, immune checkpoint inhibitors, and radiation therapy — making this a clinically important category of cardiology thesis topics at American cancer centers and academic medical centers with integrated cardio-oncology programs.

166. Investigating the left ventricular dysfunction incidence and recovery patterns in American breast cancer patients receiving anthracycline-containing chemotherapy followed by trastuzumab using serial cardiac magnetic resonance imaging
167. Analyzing the immune checkpoint inhibitor-related myocarditis incidence, clinical presentation patterns, and outcomes in American oncology patients using pharmacovigilance and electronic health record methodology
168. Developing a cardio-oncology risk stratification and surveillance protocol for American cancer patients initiating high-cardiotoxicity-risk treatment regimens and evaluating its effectiveness in reducing cardiac events
169. Characterizing the radiation-induced cardiovascular disease patterns and their temporal relationship to thoracic radiation therapy dose and field in American Hodgkin lymphoma survivors
170. Investigating the angiotensin-converting enzyme inhibitor and beta-blocker cardioprotection effectiveness during anthracycline chemotherapy for preventing left ventricular dysfunction in American breast cancer patients
171. Analyzing the cardiovascular risk factor burden and incident major adverse cardiac events in American cancer survivors compared to age-matched non-cancer controls using population-based cohort methodology
172. Developing a multidisciplinary cardio-oncology clinic model for American cancer centers and evaluating its impact on cardiovascular monitoring quality and cancer treatment completion rates
173. Characterizing the QTc prolongation patterns and potentially fatal arrhythmia risk associated with combination cancer therapy regimens in American oncology practice using pharmacovigilance methodology
174. Investigating the vascular endothelial growth factor inhibitor hypertension management effectiveness and cardiovascular outcome consequences in American patients with metastatic renal cell carcinoma
175. Analyzing the CAR-T cell therapy cardiovascular toxicity spectrum — including cytokine release syndrome-related hemodynamic compromise — and management protocols across American academic cancer centers

12. Emerging Frontiers in Cardiology

Emerging frontiers in cardiology encompass the most innovative and scientifically exciting research directions — including RNA-based cardiovascular therapeutics, cardiac regeneration, cardiovascular applications of artificial intelligence, and the cardiovascular consequences of climate change — creating a forward-looking category of cardiology thesis topics that engages graduate students with the discoveries and technologies that will define cardiovascular medicine in the coming decades.

176. Investigating the inclisiran RNA interference therapy long-term low-density lipoprotein cholesterol reduction durability and cardiovascular outcome effects in American high-risk atherosclerotic cardiovascular disease populations
177. Analyzing the cardiac regeneration potential of induced pluripotent stem cell-derived cardiomyocyte transplantation in American patients with ischemic cardiomyopathy using phase one clinical trial safety and efficacy data
178. Developing a large language model-based cardiovascular clinical decision support tool and evaluating its accuracy for evidence-based treatment recommendation generation in American outpatient cardiology settings
179. Characterizing the cardiovascular health consequences of climate change-related extreme heat events in American populations with established cardiovascular disease using time-series epidemiological methodology
180. Investigating the microbiome-cardiovascular disease axis mechanisms and therapeutic targeting potential using fecal microbiota transplantation in American patients with heart failure and gut microbiome dysbiosis
181. Analyzing the polygenic risk score clinical utility for cardiovascular risk stratification and preventive therapy personalization in American adults from diverse ancestry backgrounds
182. Developing a digital twin cardiovascular simulation platform for American heart failure patients integrating hemodynamic monitoring data and electronic health records for personalized treatment optimization
183. Characterizing the cardiovascular effects of air pollution exposure reduction following clean energy transition policies in American cities using interrupted time series and natural experiment methodology
184. Investigating the epigenetic modification patterns associated with cardiovascular disease risk and their reversibility following intensive lifestyle intervention in American adults with metabolic syndrome
185. Analyzing the artificial intelligence model performance for predicting atrial fibrillation from normal sinus rhythm electrocardiograms in American adults presenting for routine health screening
186. Developing a remote ischemic preconditioning protocol for American patients undergoing high-risk cardiac surgery and evaluating its myocardial protection effectiveness using troponin and imaging endpoints
187. Characterizing the gut microbiome trimethylamine N-oxide pathway contribution to atherosclerosis progression and its modification through dietary intervention in American adults with established coronary artery disease
188. Investigating the wearable continuous blood pressure monitoring device accuracy and clinical utility for hypertension management in American adults with resistant hypertension
189. Analyzing the sleep duration and quality patterns and their bidirectional relationship with cardiovascular disease incidence and progression in American adults using actigraphy and electronic health record linkage
190. Developing a precision cardiology approach for matching American heart failure patients to optimal guideline-directed medical therapy combinations using machine learning-based treatment response prediction
191. Characterizing the cardiovascular health implications of ultra-processed food consumption patterns in American adults using prospective dietary assessment and incident cardiovascular event linkage
192. Investigating the sex-specific cardiovascular risk factor patterns and optimal preventive therapy thresholds for American women with consideration of female-specific risk enhancers including autoimmune conditions
193. Analyzing the long COVID cardiovascular sequelae — including myocarditis, dysautonomia, and accelerated atherosclerosis — in American adults using electronic health record cohort and biomarker methodology
194. Developing a sports cardiology preparticipation screening protocol for American Masters athletes over fifty and evaluating its effectiveness in detecting occult cardiovascular disease before competitive events
195. Characterizing the perinatal cardiovascular risk factor emergence and its relationship to adult cardiovascular disease in American women with adverse pregnancy outcomes using longitudinal cohort methodology
196. Investigating the artificial intelligence model performance for optimizing guideline-directed medical therapy titration in American heart failure outpatient populations using reinforcement learning methodology
197. Analyzing the cardiovascular health consequences of cannabis use disorder in American adults using propensity-matched electronic health record cohort methodology with incident cardiovascular event outcomes
198. Developing a community-based automated external defibrillator deployment optimization program for American urban and rural communities using geospatial modeling of out-of-hospital cardiac arrest incidence
199. Characterizing the relationship between financial hardship, medication cost-related nonadherence, and cardiovascular outcomes in American adults with atherosclerotic cardiovascular disease using claims data linkage
200. Investigating the precision prevention potential of multi-omics biomarker profiling — integrating genomics, proteomics, and metabolomics — for identifying American adults at highest near-term cardiovascular event risk before clinical disease

The Range of Cardiology Thesis Topics

Current Issues

Cardiovascular health disparities represent perhaps the most morally urgent issue in contemporary American cardiology, as Black Americans continue to experience cardiovascular mortality rates dramatically higher than white Americans — a gap that has widened in recent decades despite overall improvements in cardiovascular outcomes. The excess cardiovascular burden borne by Black Americans reflects the cumulative biological embedding of chronic stress from structural racism, residential segregation’s consequences for neighborhood food and physical activity environments, differential exposure to air pollution and environmental cardiovascular hazards, and persistent disparities in the quality of preventive and acute cardiovascular care received across American health systems. Graduate students developing cardiology thesis topics that rigorously document these disparities, investigate their mechanisms, and evaluate community-engaged interventions designed to address them contribute to the most socially important research agenda in American cardiovascular medicine.

The heart failure epidemic in the United States has reached a scale that challenges the capacity of American health systems to provide adequate preventive and management care — with more than six million Americans currently living with heart failure, projections of continued growth driven by the aging population and rising rates of obesity and diabetes, and inadequate implementation of now-proven guideline-directed medical therapy across American cardiology and primary care practices. The four-pillar pharmacotherapy regimen — combining angiotensin receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — has been demonstrated to dramatically reduce mortality and hospitalization in heart failure with reduced ejection fraction, yet the majority of eligible American patients are not receiving all four agents at target doses. Graduate students developing cardiology thesis topics that investigate implementation barriers to guideline-directed medical therapy and evaluate strategies for closing the treatment gap contribute to an urgent clinical quality improvement challenge.

The cardiovascular safety and benefit profile of the therapeutic revolution in obesity and diabetes pharmacotherapy — centered on GLP-1 receptor agonists like semaglutide and tirzepatide — is reshaping preventive cardiology practice and creating a new frontier of research questions about the mechanisms through which these agents reduce cardiovascular events, the patient populations most likely to benefit, and the long-term cardiovascular consequences of sustained significant weight loss in Americans with obesity-related cardiovascular disease. As these medications become among the most widely prescribed drugs in American medicine, understanding their cardiovascular effects across diverse patient populations and clinical contexts becomes increasingly important for optimizing their use in American preventive cardiology.

Recent Trends

Transcatheter structural heart disease interventions have undergone a profound expansion of both indication and patient population — with transcatheter aortic valve replacement now approved for low-surgical-risk patients across all ages, transcatheter mitral and tricuspid valve therapies receiving expanded indications, and a pipeline of novel transcatheter devices advancing through American clinical trials. The research community is actively investigating the long-term durability of transcatheter valve prostheses, the optimal management of concurrent conditions including atrial fibrillation and coronary artery disease in structural heart disease patients, and the quality and efficiency of multidisciplinary heart team decision-making in American structural heart disease programs. Graduate students developing cardiology thesis topics in structural heart disease contribute to evidence that is directly shaping clinical practice guidelines and regulatory decisions affecting millions of American patients.

Artificial intelligence in cardiology has advanced from proof-of-concept demonstrations to clinical deployment — with AI-assisted echocardiography interpretation, electrocardiogram analysis, and cardiac imaging quantification tools being integrated into American cardiology workflows at academic and community practice settings. The most clinically exciting AI cardiology applications include algorithms that can detect atrial fibrillation, left ventricular dysfunction, and aortic stenosis from single-lead wearable device electrocardiograms — enabling screening at a scale previously impossible — and deep learning systems that can predict future cardiovascular events from routine electrocardiograms in apparently healthy individuals. Graduate students at the intersection of cardiology and AI research are contributing to both the development of these tools and the rigorous clinical evaluation frameworks needed to determine their real-world impact on American cardiovascular outcomes.

Future Directions

RNA-based cardiovascular therapeutics represent the most transformative pharmacological frontier in contemporary cardiology — with small interfering RNA agents including inclisiran demonstrating sustained low-density lipoprotein cholesterol reduction with twice-yearly dosing, antisense oligonucleotides targeting lipoprotein(a) showing dramatic reductions in this genetically determined cardiovascular risk factor, and RNA interference approaches targeting transthyretin offering disease-modifying therapy for transthyretin amyloid cardiomyopathy. Future cardiology thesis topics will evaluate the cardiovascular outcome benefits of these novel RNA therapeutic modalities, investigate the patient selection criteria and implementation strategies for integrating them into American preventive cardiology practice, and examine the health economic implications of high-cost highly effective cardiovascular RNA therapeutics for American payers and health systems.

Cardiac regeneration — the biological repair and functional restoration of damaged myocardium following myocardial infarction or the progressive cardiomyocyte loss of chronic heart failure — represents a long-sought but not yet realized goal of cardiovascular biology that is being actively pursued through stem cell transplantation, direct cardiac reprogramming, and gene therapy approaches in American cardiovascular research programs. Future cardiology thesis topics will evaluate the clinical translation of the most promising cardiac regeneration strategies, investigate the biological barriers to meaningful myocardial repair in the human heart, and develop the outcome assessment methodologies needed to detect functionally meaningful cardiac regeneration in American clinical trial participants. As the scientific understanding of cardiomyocyte biology advances and gene and cell therapy platforms mature, cardiac regeneration research will represent one of the most scientifically ambitious and potentially transformative frontiers available to graduate students in cardiovascular medicine.

Conclusion

The 200 cardiology thesis topics presented across these twelve categories reflect the extraordinary breadth of a discipline that spans coronary artery disease and heart failure, arrhythmia management and preventive cardiology, cardiac imaging and structural heart interventions, cardiovascular genetics and cardio-oncology, health disparities and emerging therapeutic frontiers. Students pursuing cardiology thesis topics at American universities engage with research questions that address the leading cause of American mortality — questions whose answers will determine whether cardiovascular disease continues its historical decline or whether rising rates of obesity, diabetes, and health inequality reverse the hard-won gains of decades of cardiovascular research and clinical innovation. Career pathways extend into academic cardiology, cardiovascular epidemiology, interventional and electrophysiology fellowship research, pharmaceutical cardiovascular clinical development, health policy, and global cardiovascular health — all domains where rigorously trained cardiology scholars make lasting contributions to reducing the devastating burden of heart disease in America.

Academic Support

iResearchNet provides expert academic support for graduate students developing cardiology thesis topics across the full spectrum of this discipline’s basic science, clinical, epidemiological, and health policy dimensions. Our consultants bring specialized expertise in coronary artery disease, heart failure, cardiac electrophysiology, preventive cardiology, cardiac imaging, structural heart disease, cardiovascular genetics, cardio-oncology, cardiovascular health disparities, and emerging cardiovascular therapeutics — with direct experience supporting students in American cardiology fellowship research programs, cardiovascular epidemiology doctoral training, clinical research fellowships, and health services research programs focused on cardiovascular care. Whether you are designing a randomized cardiovascular prevention trial, analyzing registry data from a national cardiovascular database, developing a cardiac imaging AI validation study, building a health disparities research program, or evaluating a novel heart failure management intervention, iResearchNet’s support is oriented toward strengthening your scholarly development and deepening your engagement with cardiology as a research discipline. Our mission is to support your intellectual growth, not to substitute for the original thinking that defines excellent graduate scholarship in cardiology.